ClinicalTrials.Veeva
Menu

Find clinical trials for Kidney Disease in Baltimore, MD

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Kidney Diseases
Chronic Renal Insufficiency
Chronic Kidney Failure
IGA Glomerulonephritis
Renal Cell Carcinoma
Renal Insufficiency
Carcinoma

Kidney Disease trials near Baltimore, MD, USA:

Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease

will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney...

Enrolling
Hyperphosphatemia Related to Chronic Kidney Disease
Drug: ferric citrate

Phase 3

Keryx Biopharmaceuticals

Baltimore, Maryland, United States and 12 other locations

is to evaluate the effect of tolvaptan on the need for renal replacement therapy in pediatric subjects with autosomal recessive polycystic kidney...

Enrolling
Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Drug: Tolvaptan (OPC-41061)

Phase 3

Otsuka
Otsuka

Baltimore, Maryland, United States and 17 other locations

The main objective of this study is to evaluate the safety, efficacy and pharmacokinetics of paricalcitol oral solution in pediatric participants of...

Enrolling
Chronic Kidney Disease (CKD)
Secondary Hyperparathyroidism (SHPT)
Drug: Paricalcitol

Phase 3

AbbVie
AbbVie

Washington, District of Columbia, United States and 12 other locations

A) or REGN5458 (Part B) as monotherapy in patients with chronic kidney disease (CKD) who need kidney transplantation and a...

Enrolling
Chronic Kidney Disease (CKD)
Drug: REGN5458
Drug: REGN5459

Phase 1, Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Baltimore, Maryland, United States and 8 other locations

New

and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney...

Begins enrollment in 2 months
Chronic Kidney Disease and Hypertension
Drug: Baxdrostat/dapagliflozin
Drug: Placebo/dapagliflozin

Phase 3

AstraZeneca
AstraZeneca

Fairfax, Virginia, United States and 319 other locations

To assess the impact of RGLS8429 on height-adjusted total kidney volume (htTKV)* To characterize the pharmacokinetic (PK) properties of RGLS...

Enrolling
Polycystic Kidney, Autosomal Dominant
Autosomal Dominant Polycystic Kidney Disease
Drug: Placebo
Drug: RGLS8429

Phase 1

Regulus Therapeutics

Baltimore, Maryland, United States and 27 other locations

to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney...

Active, not recruiting
Chronic Kidney Disease With High Proteinuria
Drug: Dapagliflozin
Drug: Zibotentan/Dapagliflozin

Phase 3

AstraZeneca
AstraZeneca

Silver Spring, Maryland, United States and 295 other locations

of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys...

Enrolling
Chronic Kidney Diseases
Type 2 Diabetes Mellitus
Biological: Renal Autologous Cell Therapy (REACT)
Procedure: Sham Comparator

Phase 3

Prokidney

Takoma Park, Maryland, United States and 55 other locations

safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of DISC-0974 in adult participants with Non-Dialysis Dependent Chronic Kidney...

Enrolling
Anemia of Chronic Kidney Disease
Chronic Kidney Diseases
Drug: DISC-0974
Drug: Placebo

Phase 1

Disc Medicine

Alexandria, Virginia, United States and 11 other locations

The primary objective of this study is to evaluate the safety of tolvaptan in pediatric subjects with autosomal recessive polycystic kidney ...

Enrolling
Autosomal Recessive Polycystic Kidney (ARPKD)
Drug: Tolvaptan Suspension
Drug: Tolvaptan Tablets

Phase 3

Otsuka
Otsuka

Baltimore, Maryland, United States and 27 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems